Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stockholm - Free Realtime Quote SEK

ProstaLund AB (publ) (PLUN.ST)

7.45
+0.50
+(7.19%)
As of 2:21:54 PM GMT+2. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Mr. Anders Kristensson Chief Executive Officer 2.29M -- 1974
Mr. Niclas Nystroom Chief Financial Officer -- -- 1965
Mr. Johan Laven Director of Sales & Marketing -- -- 1973

ProstaLund AB (publ)

Scheelevägen 19
Lund, 223 63
Sweden
46 46 12 09 08 https://prostalund.se
Sector: 
Healthcare
Full Time Employees: 
9

Description

ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow soft stent; Oruflow, a urine flow meter; Dosi-Fuser, a disposable continuous infusion system; and Dosi-Flow, a gravitation unit with a flow regulator for dosing of medicines. The company also provides Schelin Catheter, an injection tool that allows the urologists to administer drugs into the prostate in a sterile way through the urethra. Its products are used in hospitals and clinics. The company was founded in 1991 and is based in Lund, Sweden. ProstaLund AB (publ) is a subsidiary of Farstorps Gard Forvaltnings AB.

Corporate Governance

ProstaLund AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events